Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most claims are generic statements about dosing adjustment and monitoring that are not substantiated by the provided COSENTYX label excerpts; some parts (e.g., immune-modulating effects) are conceptually consistent with immunology-related label language but are not explicitly supported by the excerpts. Several safety-related call-to-action instructions are not directly supported from the provided sections.
Category Scores
Accurate Statements
Changing Cosentyx dose or frequency can increase the risk that symptoms return or worsen.
No explicit label support provided in the supplied excerpts (only infections/TB/IBD/hypersensitivity/immunizations/latex/warnings/interactions generalities). Marked as not verifiable from supplied text.
Unsupported Statements
Cosentyx dosing is typically based on the specific condition and disease severity.
Not supported by the provided label excerpts (no dosing section content or indication-specific dosing guidance included).
Whether a lower dose or less frequent dosing works depends on the patient's diagnosis and symptom control.
Not supported by provided label excerpts (no step-down/lower-dose evidence or guidance).
Dose-reduction strategies are usually initiated by the prescriber after stable disease control is achieved.
Not supported by provided label excerpts (no guidance on dose reduction timing or initiation criteria).
The goal of step-down is to maintain response while lowering exposure.
Not supported by provided label excerpts (no ‘step-down’ concept or treatment goal language).
Reducing dosage can involve extending the time between injections (lower frequency).
Not supported by provided label excerpts (no dosing/frequency adjustment guidance).
Reducing dosage can involve moving from an induction regimen to a maintenance regimen.
Not supported by provided label excerpts (no regimen definitions or induction vs maintenance dosing content).
Reducing dosage can involve using a lower amount per dose if the prescriber considers it appropriate.
Not supported by provided label excerpts (no mention of dose reductions to lower per-dose amount).
Many patients who successfully step down do so only after sustained control and with a monitoring plan.
Not supported by provided label excerpts (no step-down outcomes or monitoring plan language).
If a flare occurs, a clinician may restart the previous schedule or adjust again.
Not supported by provided label excerpts (no flare/step-up or restart schedule guidance).
Patients should contact their prescriber before changing Cosentyx if they have recurrent infections or a recent serious infection.
Label excerpt provides instruction to ‘seek medical advice if signs or symptoms suggestive of an infection occur’ and ‘discontinue… until the infection resolves’ but does not provide a patient directive specifically about contacting the prescriber before changing treatment.
Patients should contact their prescriber before changing Cosentyx if they have tuberculosis exposure or history.
Label excerpt requires TB evaluation before initiation and monitoring during/after treatment, but does not state this specific ‘contact before changing’ patient instruction.
Patients should contact their prescriber before changing Cosentyx if they are pregnant, planning pregnancy, or breastfeeding.
No pregnancy/planning pregnancy/breastfeeding content is included in the supplied excerpts; therefore unsupported.
Patients should contact their prescriber before changing Cosentyx if symptoms are worsening or the condition is not controlled.
Label excerpts provided do not include instructions framed as contacting prescriber before changing dosing/frequency based on symptom worsening/non-control.
Cosentyx has immune-modulating effects.
Not explicitly supported by supplied excerpts. While the label discusses immune response alteration to live vaccines and immune system disorders, the specific wording ‘immune-modulating effects’ is not directly quoted or clearly stated in the provided text.
Clinicians usually want to weigh timing and safety before any change in Cosentyx dosing.
Not supported by provided label excerpts (no statements about clinician practice patterns or decision-making framework for timing changes).
Cosentyx dosing and step-down feasibility depend on labeling and the prescriber's judgment for the patient's condition and response.
Not supported by provided label excerpts (no step-down feasibility guidance; label excerpt does not discuss prescriber judgment for step-down).
Contradictions
Important Omissions
Specific COSENTYX dosing/administration and any labeled constraints or approved dosing schedules (including whether/how dosing can be reduced, and under what labeled circumstances).
Importance:
Moderate
Any boxed warning (if present) or explicit label warnings about contraindications/precautions related to changing therapy that would be relevant to the ‘contact prescriber before changing’ claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims provide general dosing step-down concepts and patient instructions that are not supported by the provided label excerpts. The most consequential unsupported elements relate to changing dosing/frequency and to special population guidance (pregnancy/breastfeeding), which are not present in the supplied text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most statements about step-down/dose reduction, flare-based restarting schedules, and patient contact instructions are not supported by the supplied FDA label excerpts; pregnancy-related guidance is absent from the provided text.
Suggested Improvement
Remove or rephrase all step-down/dose-reduction and ‘contact before changing’ claims unless the exact supporting label language (or prescribing instructions) is provided. For immune-modulating wording, use label-anchored phrasing present in the excerpt (e.g., ‘may alter immune response to live vaccines’). For pregnancy/breastfeeding, only include statements that are supported by the provided label sections.